DNA methylation of RASSF1A, HIN-1, RAR-β, cyclin D2 and twist in in situ and invasive lobular breast carcinoma

International Journal of Cancer

Volumn 107, Issue 6, 2003, Pages 970-975

  Fackler, Mary Jo ^a   McVeigh, Megan ^a   Evron, Ella ^a,c   Garrett, Elizabeth ^a   Mehrotra, Jyoti ^a   Polyak, Kornelia ^b   Sukumar, Saraswati ^a   Argani, Pedram ^a,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c RABIN MEDICAL CENTER   (Israel)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Breast cancer; DCIS; Ductal; LCIS; Lobular; Methylation

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CARCINOMA IN SITU; CYCLIN D2 GENE; DNA METHYLATION; GENE; HIN 1 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RAR BETA GENE; RASSF1A GENE; TWIST GENE;

ADULT; BASE SEQUENCE; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; CYCLINS; CYTOKINES; DNA METHYLATION; DNA PRIMERS; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MIDDLE AGED; MULTIGENE FAMILY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; RECEPTORS, RETINOIC ACID; REFERENCE VALUES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; TWIST TRANSCRIPTION FACTOR;

EID: 0242677806     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11508     Document Type: Article

References (50)

1. Nacht M, Ferguson AT, Zhang W, Petroziello JM, Cook BP, Gao YH, Maguire S, Riley D, Coppola G, Landes GM, Madden SL, Sukumar S. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999;59:5464-70.
2. Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, Riggins G, Polyak K. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res 2001;61:5697-702.
3. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 2001;20:3348-53.
4. Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 2001;61:2782-7.
5. Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S, Sacchi N. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene 2000;19:1556-63.
6. Bovenzi V, Momparler RL. Antineoplastic action of 5-aza-2′ -deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol 2001;48:71-6.
7. Fujii H, Biel MA, Zhou W, Weitzman SA, Baylin SB, Gabrielson E. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer. Oncogene 1998;16:2159-64.
8. Mielnicki LM, Ying AM, Head KL, Asch HL, Asch BB. Epigenetic regulation of gelsolin expression in human breast cancer cells. Exp Cell Res 1999;249:161-76.
9. Wajed SA, Laird PW, DeMeester TR. DNA methylation: an alternative pathway to cancer. Ann Surg 2001;234:10-20.
10. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002;21:5462-82.
11. Rountree MR, Bachman KE, Herman JG, Baylin SB. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001;20:3156-65.
12. Mielnicki LM, Asch HL, Asch BB. Genes, chromatin, and breast cancer: an epigenetic tale. J Mammary Gland Biol Neoplasia 2001;6:169-82.
13. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
14. Lapidus RG, Nass SJ, Davidson NE. The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 1998;3:85-94.
15. Yang X, Ferguson AT, Nass SJ, Phillips DL, Butash KA, Wang SM, Herman JG, Davidson NE. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res 2000;60:6890-4.
16. Bovenzi V, Le NL, Cote S, Sinnett D, Momparler LF, Momparler RL. DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2′-deoxycytidine. Anticancer Drugs 1999;10:471-6.
17. Krop IE, Sgroi D, Porter DA, Lunetta KL, LeVangie R, Seth P, Kaelin CM, Rhei E, Bosenberg M, Schnitt S, Marks JR, Pagon Z, et al. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci USA 2001;98:9796-801.
18. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001;20:1509-18.
19. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001;61:3105-9.
20. Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 1997;272:22322-9.
21. Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE, Graff JR. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res 2000;60:4346-8.
22. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR, Sukumar S. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci USA 2000;97:6049-54.
23. Raman V, Martensen SA, Reisman D, Evron E, Odenwald WF, Jaffee E, Marks J, Sukumar S. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 2000;405:974-8.
24. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
25. Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 2000;88:2561-9.
26. Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 2003;289:1421-4.
27. Verkooijen HM, Fioretta G, Vlastos G, Morabia A, Schubert H, Sappino AP, Pelte MF, Schafer P, Kurtz J, Bouchardy C. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 2003;104:778-81.
28. Rosen PP, eds. Rosen's breast pathology, 2nd ed. Philadelphia: Lippincott Williams and Wilkins, 2001.
29. Mercapide J, Zhang SY, Fan X, Furio-Bacete V, Schneider J, Lopez de la Osa I, Patchefsky AS, Klein-Szanto AJ, Castresana JS. CCND-1 and ERBB2-gene deregulation and PTEN mutation and analyses in invasive lobular carcinoma of the breast. Mol Carcinog 2002;35:6-12.
30. Gunther K, Merkelbach-Bruse S, Amo-Takyi BK, Handt S, Schroder W, Tietze L. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 2001;193:40-7.
31. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 2001;115:85-98.
32. Jacobs TW, Pliss N, Kouria G, Schnitt SJ. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am J Surg Pathol 2001;25:229-36.
33. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001;92:404-8.
34. Lehmann U, Celikkaya G, Hasemeier B, Langer F, Kreipe H. Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype. Cancer Res 2002;62:6634-8.
35. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE, Sukumar S. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001;357:1335-6.
36. Lee MS, Lowe GN, Strong DD, Wergedal JE, Glackin CA. TWIST, a basic helix-loop-helix transcription factor, can regulate the human osteogenic lineage. J Cell Biochem 1999;75:566-77.
37. Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH, Hannon GJ. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 1999;13:2207-17.
38. Hamamori Y, Sartorelli V, Ogryzko V, Puri PL, Wu HY, Wang JY, Nakatani Y, Kedes L. Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell 1999;96:405-13.
39. Page DL, Anderson TJ, eds. Diagnostic histopathology of the breast. London: Churchill Livingstone, 1987.
40. Sweeney KJ, Sarcevic B, Sutherland RL, Musgrove EA. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene 1997;14:1329-40.
41. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002;160:605-12.
42. Seewaldt VL, Johnson BS, Parker MB, Collins SJ, Swisshelm K. Expression of retinoic acid receptor beta mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ 1995;6:1077-88.
43. Raffo P, Emionite L, Colucci L, Belmondo F, Moro MG, Bollag W, Toma S. Retinoid receptors: pathways of proliferation inhibition and apoptosis induction in breast cancer cell lines. Anticancer Res 2000;20:1535-43.
44. Zhang XK, Liu Y, Lee MO. Retinoid receptors in human lung cancer and breast cancer. Mutat Res 1996;350:267-77.
45. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-9.
46. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA 2001;98:7504-9.
47. Lee MG, Kim HY, Byun DS, Lee SJ, Lee CH, Kim JI, Chang SG, Chi SG. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 2001;61:6688-92.
48. Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res 2001;61:7034-8.
49. Yoon JH, Dammann R, Pfeifer GP. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 2001;94:212-7.
50. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, Avruch J. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 2002;21:1381-90.